Intelligent Bio Solutions (INBS) closed at $1.76 on November 13, 2026, down 8.8% from the previous close, on volume of 56,825 shares (30-day average 45,433).
Data as of November 13, 2026.
Intelligent Bio Solutions GAAP EPS of -$0.86, revenue of $1.39M
Seeking Alpha News (Tue, 10-Nov 3:18 PM ET)
Globe Newswire (Tue, 10-Nov 8:30 AM ET)
Intelligent Bio Solutions to Present at the Webull Biotech Webinar on November 12
Globe Newswire (Wed, 4-Nov 8:30 AM ET)
Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET
Globe Newswire (Thu, 10-Sep 8:30 AM ET)
Globe Newswire (Wed, 9-Sep 8:30 AM ET)
Globe Newswire (Tue, 1-Sep 8:31 AM ET)
Globe Newswire (Tue, 1-Sep 8:30 AM ET)
Globe Newswire (Wed, 19-Aug 8:30 AM ET)
Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification
Globe Newswire (Mon, 17-Aug 8:30 AM ET)
INBS Anticipates 48% Quarterly Revenue Growth—Reader Sales More Than Double for Fiscal Q2 2026
Market Chameleon (Thu, 5-Feb 4:32 AM ET)
Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.
Intelligent Bio Solutions trades on the NASDAQ stock market under the symbol INBS.
As of November 13, 2026, INBS stock price declined to $1.76 with 56,825 million shares trading.
INBS has a beta of 0.98, meaning it tends to be less sensitive to market movements. INBS has a correlation of 0.01 to the broad based SPY ETF.
INBS has a market cap of $5.84 million. This is considered a Sub-Micro Cap stock.
Last quarter Intelligent Bio Solutions reported $1 million in Revenue and -$.86 earnings per share. This fell short of revenue expectation by $-8,000 and exceeded earnings estimates by $.45.
In the last 3 years, INBS traded as high as $117.00 and as low as $1.35.
The top ETF exchange traded funds that INBS belongs to (by Net Assets): VXF.
INBS has underperformed the market in the last year with a return of -75.4%, while the SPY ETF gained +13.4%. In the last 3 month period, INBS fell short of the market, returning -41.3%, while SPY returned -2.8%. However, in the most recent 2 weeks INBS has outperformed the stock market by returning 0.0%, while SPY returned -0.2%.
INBS support price is $1.79 and resistance is $2.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INBS shares will trade within this expected range on the day.
